---
schema_version: "secwatch.filing_event.v1"
accession: "0001842952-24-000050"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2024-07-10T23:59:59+00:00"
generated_at: "2026-05-31T22:14:08.462241+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics acquires CT-95 (mesothelin x CD3 T cell engager) for $3.75M

## Summary
- Acquired CT-95 from Link (assignment for benefit of creditors) for $3.75M upfront payment.
- CT-95 is IND-cleared; Phase 1 trial expected to initiate in Q1 2025.
- Targets mesothelin, prevalent in ovarian, lung, and pancreatic cancers.
- Advancement through Phase 1 dose escalation to be funded with existing cash.

## SEC filing metadata
- accession: 0001842952-24-000050
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2024-07-10T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000184295224000050/0001842952-24-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000184295224000050/cntx-20240709.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001842952-24-000050
- JSON: https://secwatch.observer/filing/0001842952-24-000050.json
- Plain text: https://secwatch.observer/filing/0001842952-24-000050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.